Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04139434 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
A Phase 1 study, sponsored by Newave Pharmaceutical.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04139434 is a Phase 1 study that has completed, run by Newave Pharmaceutical. The registered enrollment target is 32 participants.
The verdict
NCT04139434, a Phase 1 study, has completed, sponsored by Newave Pharmaceutical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Interventions
- DRUG LP-108
- DRUG LP-108 and azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-07-06 |
| Est. Completion | 2025-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04139434
The ClinicalTrials.gov registry entry for NCT04139434 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Newave Pharmaceutical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LP-108 is the first listed.
NCT04139434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04139434 about?
NCT04139434 is a clinical study titled "Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML". A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelom...
What is the current status of trial NCT04139434?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2020-07-06. Estimated completion is 2025-12-19.
What interventions are being tested in trial NCT04139434?
The interventions under investigation include: LP-108 (DRUG), LP-108 and azacitidine (DRUG).
Who is sponsoring clinical trial NCT04139434?
This trial is sponsored by Newave Pharmaceutical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.